CONCORDBIO vs NECLIFE: Stock Comparison
CONCORD BIOTECH is the larger company by market capitalisation. CONCORD BIOTECH shows a higher ROE, a higher dividend yield and a higher ROCE, while NECTAR LIFESCIENCES shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CONCORDBIO leads 5; NECLIFE leads 4 of 12
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CONCORDBIO | NECLIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CONCORDBIO | NECLIFE |
|---|---|---|
| Live Price | ₹1,245.1 | ₹10.32 |
| Day Change | 1.18% | -0.1% |
| Volume | 40,093 | 14,129 |
| 52-Week High | ₹1,615 | ₹21.4 |
| 52-Week Low | ₹987 | ₹9.3 |
| Distance from 52W High | -22.9% | -51.78% |
Valuation
| Metric | CONCORDBIO | NECLIFE |
|---|---|---|
| Market Cap | ₹13,008 Cr | ₹203 Cr |
| P/E Ratio | 45.59x | 0x |
| P/B Ratio | 6.2x | 0.4x |
| EPS | ₹26.71 | ₹-0.79 |
| Book Value | ₹195.37 | ₹29.97 |
| Dividend Yield | 0.6% | 0% |
Growth
| Metric | CONCORDBIO | NECLIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | -24.1% | -3.41% |
| EPS Growth (TTM YoY) | -37% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | CONCORDBIO | NECLIFE |
|---|---|---|
| ROE | 13.03% | -9.85% |
| ROCE | 13.09% | -8.89% |
| Net Margin | 24.6% | -11.28% |
| Operating Margin | 33.33% | — |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CONCORDBIO | NECLIFE |
|---|---|---|
| Promoter Holding | 44.09%▲ 0.01 pp | 51.84% |
| FII Holding | 7.28%▼ 0.24 pp | 0.5% |
| DII Holding | 10.95%▲ 1.59 pp | 3.9%▲ 0.16 pp |
| Public Holding | 37.68%▼ 1.35 pp | 43.74%▼ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CONCORD BIOTECH and NECTAR LIFESCIENCES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.